Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04998552 · ClinicalTrials.gov registry record · NA
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
A NA study of Pancreas Adenocarcinoma, sponsored by Capital Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04998552 is a NA study of Pancreas Adenocarcinoma that is actively recruiting participants, run by Capital Health System. The registered enrollment target is 10 participants, below the 78-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04998552, a NA study of Pancreas Adenocarcinoma, is actively recruiting participants, sponsored by Capital Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
Conditions Studied
Interventions
- RADIATION Cyberknife
Study Locations (1)
New Jersey
- Capital Health Medical Center-Hopewell - Pennington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2027-06-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04998552
The ClinicalTrials.gov registry entry for NCT04998552 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Capital Health System, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cyberknife is the first listed.
NCT04998552 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04998552 about?
NCT04998552 is a clinical study titled "Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma". The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
What is the current status of trial NCT04998552?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2021-06-22. Estimated completion is 2027-06-22.
What conditions does trial NCT04998552 study?
This clinical trial studies the following conditions: Pancreas Adenocarcinoma.
What interventions are being tested in trial NCT04998552?
The interventions under investigation include: Cyberknife (RADIATION).
Who is sponsoring clinical trial NCT04998552?
This trial is sponsored by Capital Health System, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04998552 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetic Testing Decision Aid
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
RECRUITING · Phase 2
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.